UniQure Advances AMT-191 Trial in Fabry Disease

MT Newswires Live

2025/02/04

UniQure (QURE) said Monday that it has completed enrollment in the first cohort of patients of the phase 1/2a trial of its gene therapy candidate, AMT-191, for the treatment of Fabry disease.

The firm also said the Independent Data Monitoring Committee recommended proceeding with enrollment in the second cohort after it found no significant safety concerns following a safety data review from the first cohort's initial two patients.

The company said it expects to initiate enrollment of second dose cohort in the first quarter of 2025.

Price: 15.47, Change: -0.27, Percent Change: -1.72

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2508125828"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2508125828\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2508125828?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-04 01:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2508125828","market":"sh","top_or_hot":-1,"title":"UniQure Advances AMT-191 Trial in Fabry Disease","media":"MT Newswires Live","content":"<html><body><p> UniQure (QURE) said Monday that it has completed enrollment in the first cohort of patients of the phase 1/2a trial of its gene therapy candidate, AMT-191, for the treatment of Fabry disease.</p><p>The firm also said the Independent Data Monitoring Committee recommended proceeding with enrollment in the second cohort after it found no significant safety concerns following a safety data review from the first cohort's initial two patients.</p><p>The company said it expects to initiate enrollment of second dose cohort in the first quarter of 2025.</p><p>Price: 15.47, Change: -0.27, Percent Change: -1.72</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>UniQure Advances AMT-191 Trial in Fabry Disease</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUniQure Advances AMT-191 Trial in Fabry Disease\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2025-02-04 01:08</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> UniQure (QURE) said Monday that it has completed enrollment in the first cohort of patients of the phase 1/2a trial of its gene therapy candidate, AMT-191, for the treatment of Fabry disease.</p><p>The firm also said the Independent Data Monitoring Committee recommended proceeding with enrollment in the second cohort after it found no significant safety concerns following a safety data review from the first cohort's initial two patients.</p><p>The company said it expects to initiate enrollment of second dose cohort in the first quarter of 2025.</p><p>Price: 15.47, Change: -0.27, Percent Change: -1.72</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4581","symbol_name":"高盛持倉","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2508125828","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2508125828","pubTimestamp":1738602502,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"UniQure  said Monday that it has completed enrollment in the first cohort of patients of the phase 1/2a trial of its gene therapy candidate, AMT-191, for the treatment of Fabry disease.The firm also said the Independent Data Monitoring Committee recommended proceeding with enrollment in the second cohort after it found no significant safety concerns following a safety data review from the first cohort's initial two patients.The company said it expects to initiate enrollment of second dose cohort in the first quarter of 2025.Price: 15.47, Change: -0.27, Percent Change: -1.72","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4581":"高盛持仓","BK4534":"瑞士信贷持仓","QURE":"uniQure N.V.","AMT":"美国电塔","BK4219":"电信塔房地产信托","BK4554":"元宇宙及AR概念","BK4084":"特种房地产投资信托","BK4588":"碎股","BK4585":"ETF&股票定投概念","BK4139":"生物科技"},"translate_title":"UniQure推进AMT-191治疗法布里病的试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"QURE":0.9,"AMT":1},"content_text":"UniQure (QURE) said Monday that it has completed enrollment in the first cohort of patients of the phase 1/2a trial of its gene therapy candidate, AMT-191, for the treatment of Fabry disease.The firm also said the Independent Data Monitoring Committee recommended proceeding with enrollment in the second cohort after it found no significant safety concerns following a safety data review from the first cohort's initial two patients.The company said it expects to initiate enrollment of second dose cohort in the first quarter of 2025.Price: 15.47, Change: -0.27, Percent Change: -1.72","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}